Insider · CIK 0001566175
Sandesh Seth
Files at ATNM (Actinium Pharmaceuticals, Inc.). First filing -, latest -.
Sandesh Seth files SEC Form 4 as CEO and director at ATNM (Actinium Pharmaceuticals, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Sandesh Seth has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 12 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 2, 2026 | ATNM Actinium Pharmaceuticals, Inc. | AGrant or award Common Stock | +753,600 | $0.00 | $0 | 938,081 | 39 d ago |
| Sep 2, 2026 | ATNM Actinium Pharmaceuticals, Inc. | AGrant or award Common Stock | +1,027,274 | $0.00 | $0 | 1,965,355 | 39 d ago |
| Sep 2, 2026 | ATNM Actinium Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +1,130,400 | $0.00 | $0 | 1,130,400 | 39 d ago |
| Aug 18, 2025 | ATNM Actinium Pharmaceuticals, Inc. | FTax withholding Common Stock | -120,900 | $1.71 | $207k | 184,481 | Aug 20, 2025 |
| Mar 31, 2025 | ATNM Actinium Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -16,666 | $0.00 | $0 | 0 | Apr 2, 2025 |
| Mar 31, 2025 | ATNM Actinium Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -25,000 | $0.00 | $0 | 0 | Apr 2, 2025 |
| Mar 31, 2025 | ATNM Actinium Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -33,333 | $0.00 | $0 | 0 | Apr 2, 2025 |
| Mar 31, 2025 | ATNM Actinium Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -50,000 | $0.00 | $0 | 0 | Apr 2, 2025 |
| Mar 31, 2025 | ATNM Actinium Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -139,062 | $0.00 | $0 | 0 | Apr 2, 2025 |
| Mar 31, 2025 | ATNM Actinium Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -310,182 | $0.00 | $0 | 0 | Apr 2, 2025 |
| Mar 31, 2025 | ATNM Actinium Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -827,366 | $0.00 | $0 | 0 | Apr 2, 2025 |
| Mar 31, 2025 | ATNM Actinium Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -984,367 | $0.00 | $0 | 0 | Apr 2, 2025 |
Questions about Sandesh Seth
Answered from the filings on this page, as of the latest one.
Is Sandesh Seth buying or selling?
Sandesh Seth has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Sandesh Seth's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Sandesh Seth has 0.
Where does Sandesh Seth file Form 4?
Sandesh Seth has filed Form 4 at ATNM (Actinium Pharmaceuticals, Inc.) as Chief Executive Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.